The Medicines Company Receives European Approval for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures
_—European Commission Decision based on landmark HORIZONS-AMI trial data—
PARSIPPANY, N J--(BUSINESS WIRE)--Dec. 1, 2009-- The Medicines Company (NASDAQ: MDCO) announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).
Source: The Medicines Company
